AYTUAYTU BIOPHARMA, INCvs its industry peers
A metric-by-metric comparison of AYTU BIOPHARMA, INC against Pharmaceutical Preparations — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AYTU본 종목 | $25M#8 | — | 0.7x#1 | 0.4x#1 | 1.8%#4 | 14.4%#9 | -11.8%#1 | -38.6%#3 | -41.4%#3 | 4#2 | -1.7%#5 | — |
| ARTL | $30M#1 | — | 6.1x#12 | — | — | -31.1%#13 | — | -257.7%#12 | — | — | -97.1%#15 | — |
| HEPA | $29M#2 | — | 22.4x#15 | — | — | 37.3%#7 | — | -647.5%#14 | — | — | -17.6%#7 | — |
| TXMD | $26M#3 | — | 1.0x#4 | 8.6x#5 | 71.6%#1 | 73.9%#1 | -145.3%#3 | -2.1%#2 | -3.8%#1 | 5#1 | 99.1%#1 | — |
| NNVC | $26M#4 | — | 2.8x#8 | — | — | -14.1%#11 | — | -103.4%#8 | -89.9%#6 | — | -16.9%#6 | — |
| LTRN | $25M#5 | — | — | — | — | 17.6%#8 | — | — | — | — | -54.4%#11 | — |
| ATOS | $25M#6 | — | 0.9x#3 | 14191.3x#10 | -95.6%#9 | -36.3%#14 | -2112684.9%#10 | -129.6%#9 | — | — | -78.5%#13 | — |
| TVRD | $25M#7 | — | 3.0x#9 | 3.5x#3 | -66.0%#7 | 38.1%#6 | -374.8%#6 | -217.3%#11 | — | — | -93.4%#14 | — |
| PTN | $24M#9 | 121.9x#2 | 2.3x#7 | — | -100.0%#10 | -41.8%#15 | — | 163.3%#1 | -2281.5%#9 | — | — | — |
| CLRB | $23M#10 | — | 0.8x#2 | — | — | 51.1%#3 | — | -72.9%#5 | — | — | -49.9%#10 | — |
| ABVC | $23M#11 | — | 2.2x#6 | 76.8x#9 | 0.0%#5 | -61.3%#16 | -2416.0%#8 | -76.9%#6 | -68.5%#4 | — | -68.5%#12 | — |
| BFRI | $22M#12 | — | 3.8x#10 | 0.5x#2 | 11.7%#2 | 40.7%#5 | -27.2%#2 | -176.9%#10 | -712.4%#7 | — | 78.6%#2 | — |
| COCP | $22M#13 | — | 21.2x#14 | 11.0x#7 | -69.3%#8 | 49.5%#4 | -447.8%#7 | -845.9%#15 | -20.4%#2 | 3#3 | -19.6%#8 | — |
| ALLR | $22M#14 | 0.0x#1 | 6.2x#13 | 68.1x#8 | — | 54.2%#2 | -3939.1%#9 | -317.6%#13 | — | — | -25.1%#9 | — |
| CYCN | $21M#15 | — | 4.2x#11 | 10.2x#6 | 3.7%#3 | -15.4%#12 | -239.8%#4 | -69.4%#4 | -69.1%#5 | — | 70.3%#3 | — |
| MRKR | $21M#16 | — | 1.7x#5 | 5.9x#4 | -46.2%#6 | -13.3%#10 | -363.5%#5 | -100.0%#7 | -1413.6%#8 | — | 45.7%#4 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-03.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice